# An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT01838668** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 225 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis
- Multiple Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT01838668
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-28
- **Primary completion:** 2015-06-16
- **Final completion:** 2018-09-04
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2018-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838668, "An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01838668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*